ReviewAutism research : official journal of the International Society for Autism Research2026
Beyond the Outburst: Charting a New Frontier for Understanding and Treating Irritability in Autistic Adults.
Review in Autism research : official journal of the International Society for Autism Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a vulnerable neurobiology (e.g., sensory sensitivities, intolerance of uncertainty), but may also stem from intrinsic neurobiological dysregulation independent of environmental triggers. The current treatment paradigm for autistic adults, largely extrapolated from pediatric antipsychotic trials, leaves these adults critically underserved due to a lack of evidence-based treatments, clinical trials, or validated tools to measure their internal experience. This viewpoint deconstructs irritability, differentiating its affective nature from aggression, and highlights heterogeneity across the lifespan and support needs. We critique the limitations of current assessment methods and recommend a shift toward a multi-modal strategy integrating self-report (when feasible) with objective, physiologically-informed tools (e.g., wearable biosensors) and nuanced observer reports. We argue that the field is poised for neuroscience-informed treatment innovation-including novel pharmacological agents and adapted psychosocial interventions-but is hampered by a lack of rigorous clinical trials in adults. Finally, we call for mechanistically driven trials to address the large unmet burden of inadequately treated irritability, ultimately improving the quality of life for autistic adults and their families/caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.